What is the PALYNZIQ® (pegvaliase-pqpz) Injection Risk Evaluation and Mitigation Strategy (REMS)?
- A REMS is required by the FDA to ensure that the benefits of therapy outweigh the risks
- The goal of the PALYNZIQ REMS is to mitigate the risk of anaphylaxis1

Enroll yourself
- Read the full Prescribing Information for PALYNZIQ
- Read the REMS Prescriber Guide
- Read the REMS Program Overview
- Complete the REMS Prescriber Knowledge Assessment
- Sign the REMS Prescriber Enrollment Form Click here to view REMS resources

Enroll each patient
- Counsel your patient on the risks associated with PALYNZIQ, including the risk of anaphylaxis and the need for auto-injectable epinephrine
- Prescribe auto-injectable epinephrine, and instruct patients how to use it and to carry it with them at all times
- Review the following with your patient:
- REMS Patient Guide
- REMS Wallet Card
- REMS Safety Video
- You and your patient must sign the REMS Patient Enrollment Form Click here to view REMS resources
Visit PALYNZIQREMS.com or submit signed, completed forms by fax or mail to the PALYNZIQ REMS:
Phone:
Fax:
PALYNZIQ REMS, 200 Pinecrest Plaza, Morgantown, WV 26505
Reference: 1. PALYNZIQ [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2020.